BR112022021423A2 - Uso de proteína surfactante d para tratar infecções virais - Google Patents
Uso de proteína surfactante d para tratar infecções viraisInfo
- Publication number
- BR112022021423A2 BR112022021423A2 BR112022021423A BR112022021423A BR112022021423A2 BR 112022021423 A2 BR112022021423 A2 BR 112022021423A2 BR 112022021423 A BR112022021423 A BR 112022021423A BR 112022021423 A BR112022021423 A BR 112022021423A BR 112022021423 A2 BR112022021423 A2 BR 112022021423A2
- Authority
- BR
- Brazil
- Prior art keywords
- surfactant protein
- viral infections
- treat viral
- treat
- viral infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013726P | 2020-04-22 | 2020-04-22 | |
| US202063072354P | 2020-08-31 | 2020-08-31 | |
| PCT/US2021/028207 WO2021216584A1 (en) | 2020-04-22 | 2021-04-20 | Use of surfactant protein d to treat viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021423A2 true BR112022021423A2 (pt) | 2023-01-03 |
Family
ID=78270057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021423A BR112022021423A2 (pt) | 2020-04-22 | 2021-04-20 | Uso de proteína surfactante d para tratar infecções virais |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181697A1 (https=) |
| EP (1) | EP4138905A4 (https=) |
| JP (1) | JP7798791B2 (https=) |
| KR (1) | KR20230019089A (https=) |
| AU (1) | AU2021258178A1 (https=) |
| BR (1) | BR112022021423A2 (https=) |
| CA (1) | CA3180205A1 (https=) |
| IL (1) | IL297362A (https=) |
| MX (1) | MX2022013195A (https=) |
| WO (1) | WO2021216584A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023145916A1 (https=) * | 2022-01-31 | 2023-08-03 | ||
| WO2024097169A1 (en) * | 2022-11-01 | 2024-05-10 | National Jewish Health | Treatment of coronavirus infections with antimicrobial phospholipid compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933032B2 (en) * | 1998-10-20 | 2015-01-13 | Children's Hospital Medical Center | Surfactant protein D for the treatment of disorders associated with lung injury |
| US20030221199A1 (en) | 1998-10-20 | 2003-11-27 | Whitsett Jeffrey A. | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| US20120220531A1 (en) * | 2011-02-04 | 2012-08-30 | Cincinnati Children's Hospital Medical Center | Surfactant protein d for the treatment of disorders associated with lung injury |
| US20130216499A1 (en) * | 2012-02-17 | 2013-08-22 | Wenlin Huang | Compositions of recombinant human endostatin adenovirus injections and methods of production |
| NL2011626C2 (en) * | 2013-10-17 | 2015-04-20 | Stichting Tech Wetenschapp | Novel polypeptide and uses thereof. |
| JP7797098B2 (ja) * | 2018-03-29 | 2026-01-13 | エアウェイ・セラピューティクス・インコーポレイテッド | サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物 |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| KR102205028B1 (ko) * | 2020-03-22 | 2021-01-20 | (주)셀트리온 | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| CN112481417B (zh) * | 2020-12-24 | 2022-05-27 | 山西大学 | 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒 |
-
2021
- 2021-04-20 AU AU2021258178A patent/AU2021258178A1/en active Pending
- 2021-04-20 BR BR112022021423A patent/BR112022021423A2/pt unknown
- 2021-04-20 IL IL297362A patent/IL297362A/en unknown
- 2021-04-20 CA CA3180205A patent/CA3180205A1/en active Pending
- 2021-04-20 WO PCT/US2021/028207 patent/WO2021216584A1/en not_active Ceased
- 2021-04-20 US US17/920,245 patent/US20230181697A1/en active Pending
- 2021-04-20 MX MX2022013195A patent/MX2022013195A/es unknown
- 2021-04-20 KR KR1020227040749A patent/KR20230019089A/ko not_active Withdrawn
- 2021-04-20 EP EP21792923.1A patent/EP4138905A4/en active Pending
- 2021-04-20 JP JP2022564443A patent/JP7798791B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230019089A (ko) | 2023-02-07 |
| JP2023523253A (ja) | 2023-06-02 |
| US20230181697A1 (en) | 2023-06-15 |
| EP4138905A4 (en) | 2024-04-17 |
| JP7798791B2 (ja) | 2026-01-14 |
| AU2021258178A1 (en) | 2022-11-17 |
| CA3180205A1 (en) | 2021-10-28 |
| EP4138905A1 (en) | 2023-03-01 |
| IL297362A (en) | 2022-12-01 |
| MX2022013195A (es) | 2023-01-05 |
| WO2021216584A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018819A2 (pt) | Vacinas contra coronavírus e métodos de uso | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| BR112023020600A2 (pt) | Método para tratar ou prevenir uma infecção, e, uso de um composto | |
| BR112021024310A2 (pt) | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus | |
| CL2016000240A1 (es) | Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal. | |
| DOP2022000185A (es) | Compuestos antivirales y métodos para la administración de los mismos. | |
| BR112022017308A2 (pt) | Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral | |
| BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
| AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| CL2021001044A1 (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria | |
| BR112022021423A2 (pt) | Uso de proteína surfactante d para tratar infecções virais | |
| MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
| BR112022000710A2 (pt) | Vacina viral terapêutica | |
| BR112022016456A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos | |
| EP4640205A3 (en) | Oral care compositions comprising hops beta acid and fluoride | |
| BR112015019568A2 (pt) | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo | |
| BR112022019090A2 (pt) | Inibidores de c5a para o tratamento de infecção por coronavírus | |
| BR112022000971A2 (pt) | Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv | |
| BR112023002926A2 (pt) | Agentes terapêuticos inaláveis | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| PE20090653A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc | |
| UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire | |
| MX2020010932A (es) | Enzimas quinureninasa humanas y sus usos. |